A Phase 4 interventional study of Folic acid and Neurobion in Hepatitis C, sponsored by British University In Egypt. Status unknown at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2014-05-29.
Sponsored by British University In Egypt · Phase 4, Interventional, and Prevention
Since success of the combination therapy with PEG-IFN and RBV is contingent on maintaining adequate doses of both drugs throughout the treatment period, the emergence of hematological side effects is expected and requires intervention. The hematological adverse effects lead to a trade-off between continuing the treatment with optimal dosage, to clear the virus, exacerbating thereby the side effects versus decreasing dosage to relieve severe anemia, reducing thereby the chances of achieving sustained virological response (SVR). Therefore, we aimed at giving Folic acid® and Neurobion® to HCV-infected patients during treatment with different types of PEG-IFN plus ribavirin in an attempt to evaluate its efficacy and safety as a prophylactic treatment to prevent hematological adverse effects. Preventing adverse effects without interfering with the therapeutic efficacy of different types of PEG-IFN plus ribavirin in HCV patients will lead to better health outcomes and improvement in their quality of life (HRQOL).
2,709 studies on the registry are indexed under Hepatitis A; 142 are open to participants now.
This study's planned enrollment of 120 is above the median of 100 across 1,886 interventional studies indexed under Hepatitis A.
Browse Hepatitis A studies →British University In Egypt is the lead sponsor of 67 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Chronic hepatitis C patients of both sexes were eligible for inclusion if they were HCV RNA positive, naive to PEG-INF and RBV, and had abnormal serum alanine transaminase levels on two occasions during the preceding six months.
Exclusion Criteria:
Patients with significant hematological abnormalities at baseline, such as neutropenia (ANC \<1200 x 103 cells/µL), thrombocytopenia (\<70 x 103 cells/ µL), and anemia (\<10.5 g/dL), were excluded. Patients were also excluded from study participation if they had serum creatinine ≥1.70 mg/dL (150 µmol), hepatitis B surface antigen positivity, decompensated cirrhosis, or other forms of liver disease not attributable to HCV. Patients with severe depression or psychosis, uncontrolled seizures, poorly controlled cardiovascular disease, diabetes mellitus, or autoimmune disorders were also ineligible. Women were ineligible for study participation if they were pregnant or unwilling to use at least 2 forms of effective contraception during the entire study period.
one capsule of 5 mg of Folic acid twice daily and a tablet of Neurobion three times per day during hepatitis C treatment
Dietary Supplement: Folic acid · Drug: Neurobion
Patients will receive one capsule of 5 mg of Folic acid twice daily during hepatitis C treatment
Dietary Supplement: Folic acid
Patients will receive a tablet of Neurobion three times per day during hepatitis C treatment
Drug: Neurobion
Patients will receive matching placebo capsule to take during hepatitis C treatment
Drug: placebo
Effect of folic acid and/or Vitamin B complex to prevent adverse effect of pegylated interferon and ribavirin
Maintain absolute neutrophil count (ANC) levels \>750 cells/mm3, hemoglobin levels \>10.5 g/dL to prevent adjustment to the PEG-INF dose or its temporary suspension. Moreover, to maintain a sustained platelet level above 45,000 platelet/mm3. During therapy thrombocytopenia was assessed at levels of 50,000 and 25,000/µl, since these levels are the usual thresholds for dose reductions or discontinuation of peginterferon alfa/ribavirin therapy.
Time frame: 1 YEAR
Effect of folic acid and/or Vitamin B complex on the efficacy of pegylated interferon and ribavirin.
Biochemical improvement of liver function and sustained virological response (SVR). Biochemical improvement was defined as a decrease in alanine transaminase (ALT) level and Aspartate transaminase (AST). A sustained virological response (SVR) is defined as undetectable serum HCV RNA (\< 51 IU/ml) 24 weeks after the completion of treatment.
Time frame: 1 year and 6 month after end of treatment
This study is status unknown, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
British University In Egypt